ReviewDie Ophthalmologie2025
[From indications to outcome-A concise overview of supplementary intraocular lenses].
Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Supplementary intraocular lenses (IOLs) are used to correct spherical and astigmatic refractive errors after cataract surgery. They provide patients with improved uncorrected visual acuity, resulting in a higher degree of spectacle independence. For the implantation of supplementary IOLs two approaches are distinguished: the primary and secondary Duet procedures. Indications include extreme refractive errors, desire for reversible multifocality, residual refractive errors and pediatric cataract surgery. Monofocal, extended depth of focus (EDOF) and multifocal implants are available, some also as toric variants. Thanks to specialized IOL designs, supplementary IOLs have been optimized for implantation in the ciliary sulcus, making the procedure safe, effective and associated with minimal complications. Several studies have demonstrated the favorable safety profile, predictable refractive outcomes and improvement in uncorrected visual acuity. Continuous advancements in IOL design, including the availability of EDOF and multifocal implants, have further enhanced the benefits of supplementary IOLs. Through a relatively small, low-risk and quick procedure, individualized solutions can be provided for many patients, improving vision and reducing spectacle dependence.
Indexed as
Identifiers
40691357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.